A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

NCT03479307 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: Bilastine Ophthalmic Solution 0.6%
DRUG: Ketotifen Ophthalmic Solution 0.025% (Zaditen)
DRUG: Vehicle of Bilastine Ophthalmic Solution

Sponsor

Faes Farma, S.A.

Collaborators

[object Object]